-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the official website of CDE showed that Shijiazhuang's four-drug argatroban injection was accepted as a generic 4 type of argatroban injection
.
According to data from Meinenet, in 2020, the sales of terminal argatroban injection in public medical institutions in China will exceed 600 million yuan, with a year-on-year increase of more than 40% in 2021H1.
Among them, Tianjin Pharmaceutical Research Institute Pharmaceutical has the largest market share
.
.
According to data from Meinenet, in 2020, the sales of terminal argatroban injection in public medical institutions in China will exceed 600 million yuan, with a year-on-year increase of more than 40% in 2021H1.
Among them, Tianjin Pharmaceutical Research Institute Pharmaceutical has the largest market share
.
According to data, argatroban was developed by Mitsubishi Tanabe of Japan.
It is a synthetic arginine derivative that can inhibit the activity of thrombin, thereby producing an anticoagulant effect.
It has fast onset, short action time, low bleeding tendency, and no Advantages such as immunogenicity
.
It is a synthetic arginine derivative that can inhibit the activity of thrombin, thereby producing an anticoagulant effect.
It has fast onset, short action time, low bleeding tendency, and no Advantages such as immunogenicity
.
Sales of terminal argatroban injection in public medical institutions in China in recent years (unit: 100 million yuan)
Source: Terminal competition landscape of China's public medical institutions
According to data from Menet.
com, in 2020, the sales of terminal argatroban injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 600 million yuan, with a year-on-year increase of more than 40 in 2021H1.
%, among which, the pharmaceutical industry of Tianjin Institute of Pharmaceutical Research has the largest market share
.
com, in 2020, the sales of terminal argatroban injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 600 million yuan, with a year-on-year increase of more than 40 in 2021H1.
%, among which, the pharmaceutical industry of Tianjin Institute of Pharmaceutical Research has the largest market share
.
There are 7 manufacturers of argatroban injection including Tianjin Pharmaceutical Research Institute Pharmaceutical, Shandong New Times Pharmaceutical, Nanjing Zhengda Tianqing Pharmaceutical, etc.
At present, this product has not been reviewed by enterprises
.
At present, this product has not been reviewed by enterprises
.
It is worth mentioning that 15 companies for Argatroban injection have submitted listing applications for review and approval.
Among them, CSPC Ouyi Pharmaceutical | CSPC Yinhu Pharmaceutical, Sinopharm Guorui Pharmaceutical, Hunan Hengsheng More than 10 companies, including pharmaceuticals, have submitted their listing applications in the 4 types of imitations and are under review and approval.
After approval, they will be deemed to have been reviewed; the supplementary applications for consistency evaluation of Shandong New Times Pharmaceutical and Hunan Sailong Pharmaceutical are under review and approval In
.
Among them, CSPC Ouyi Pharmaceutical | CSPC Yinhu Pharmaceutical, Sinopharm Guorui Pharmaceutical, Hunan Hengsheng More than 10 companies, including pharmaceuticals, have submitted their listing applications in the 4 types of imitations and are under review and approval.
After approval, they will be deemed to have been reviewed; the supplementary applications for consistency evaluation of Shandong New Times Pharmaceutical and Hunan Sailong Pharmaceutical are under review and approval In
.
Source: CDE official website, Minet database
A few days ago, the official website of CDE showed that Shijiazhuang's four-drug argatroban injection was accepted as a generic 4 type of argatroban injection
.
According to data from Meinenet, in 2020, the sales of terminal argatroban injection in public medical institutions in China will exceed 600 million yuan, with a year-on-year increase of more than 40% in 2021H1.
Among them, Tianjin Pharmaceutical Research Institute Pharmaceutical has the largest market share
.
.
According to data from Meinenet, in 2020, the sales of terminal argatroban injection in public medical institutions in China will exceed 600 million yuan, with a year-on-year increase of more than 40% in 2021H1.
Among them, Tianjin Pharmaceutical Research Institute Pharmaceutical has the largest market share
.
According to data, argatroban was developed by Mitsubishi Tanabe of Japan.
It is a synthetic arginine derivative that can inhibit the activity of thrombin, thereby producing an anticoagulant effect.
It has fast onset, short action time, low bleeding tendency, and no Advantages such as immunogenicity
.
It is a synthetic arginine derivative that can inhibit the activity of thrombin, thereby producing an anticoagulant effect.
It has fast onset, short action time, low bleeding tendency, and no Advantages such as immunogenicity
.
Sales of terminal argatroban injection in public medical institutions in China in recent years (unit: 100 million yuan)
Source: Terminal competition landscape of China's public medical institutions
According to data from Menet.
com, in 2020, the sales of terminal argatroban injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 600 million yuan, with a year-on-year increase of more than 40 in 2021H1.
%, among which, the pharmaceutical industry of Tianjin Institute of Pharmaceutical Research has the largest market share
.
com, in 2020, the sales of terminal argatroban injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 600 million yuan, with a year-on-year increase of more than 40 in 2021H1.
%, among which, the pharmaceutical industry of Tianjin Institute of Pharmaceutical Research has the largest market share
.
There are 7 manufacturers of argatroban injection including Tianjin Pharmaceutical Research Institute Pharmaceutical, Shandong New Times Pharmaceutical, Nanjing Zhengda Tianqing Pharmaceutical, etc.
At present, this product has not been reviewed by enterprises
.
At present, this product has not been reviewed by enterprises
.
It is worth mentioning that 15 companies for Argatroban injection have submitted listing applications for review and approval.
Among them, CSPC Ouyi Pharmaceutical | CSPC Yinhu Pharmaceutical, Sinopharm Guorui Pharmaceutical, Hunan Hengsheng More than 10 companies, including pharmaceuticals, have submitted their listing applications in the 4 types of imitations and are under review and approval.
After approval, they will be deemed to have been reviewed; the supplementary applications for consistency evaluation of Shandong New Times Pharmaceutical and Hunan Sailong Pharmaceutical are under review and approval In
.
Among them, CSPC Ouyi Pharmaceutical | CSPC Yinhu Pharmaceutical, Sinopharm Guorui Pharmaceutical, Hunan Hengsheng More than 10 companies, including pharmaceuticals, have submitted their listing applications in the 4 types of imitations and are under review and approval.
After approval, they will be deemed to have been reviewed; the supplementary applications for consistency evaluation of Shandong New Times Pharmaceutical and Hunan Sailong Pharmaceutical are under review and approval In
.
Source: CDE official website, Minet database
A few days ago, the official website of CDE showed that Shijiazhuang's four-drug argatroban injection was accepted as a generic 4 type of argatroban injection
.
According to data from Meinenet, in 2020, the sales of terminal argatroban injection in public medical institutions in China will exceed 600 million yuan, with a year-on-year increase of more than 40% in 2021H1.
Among them, Tianjin Pharmaceutical Research Institute Pharmaceutical has the largest market share
.
.
According to data from Meinenet, in 2020, the sales of terminal argatroban injection in public medical institutions in China will exceed 600 million yuan, with a year-on-year increase of more than 40% in 2021H1.
Among them, Tianjin Pharmaceutical Research Institute Pharmaceutical has the largest market share
.
According to data, argatroban was developed by Mitsubishi Tanabe of Japan.
It is a synthetic arginine derivative that can inhibit the activity of thrombin, thereby producing an anticoagulant effect.
It has fast onset, short action time, low bleeding tendency, and no Advantages such as immunogenicity
.
It is a synthetic arginine derivative that can inhibit the activity of thrombin, thereby producing an anticoagulant effect.
It has fast onset, short action time, low bleeding tendency, and no Advantages such as immunogenicity
.
Sales of terminal argatroban injection in public medical institutions in China in recent years (unit: 100 million yuan)
Source: Terminal competition landscape of China's public medical institutions
According to data from Menet.
com, in 2020, the sales of terminal argatroban injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 600 million yuan, with a year-on-year increase of more than 40 in 2021H1.
%, among which, the pharmaceutical industry of Tianjin Institute of Pharmaceutical Research has the largest market share
.
Hospital hospital hospitalcom, in 2020, the sales of terminal argatroban injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 600 million yuan, with a year-on-year increase of more than 40 in 2021H1.
%, among which, the pharmaceutical industry of Tianjin Institute of Pharmaceutical Research has the largest market share
.
There are 7 manufacturers of argatroban injection including Tianjin Pharmaceutical Research Institute Pharmaceutical, Shandong New Times Pharmaceutical, Nanjing Zhengda Tianqing Pharmaceutical, etc.
At present, this product has not been reviewed by enterprises
.
Enterprise business enterpriseAt present, this product has not been reviewed by enterprises
.
It is worth mentioning that 15 companies for Argatroban injection have submitted listing applications for review and approval.
Among them, CSPC Ouyi Pharmaceutical | CSPC Yinhu Pharmaceutical, Sinopharm Guorui Pharmaceutical, Hunan Hengsheng More than 10 companies, including pharmaceuticals, have submitted their listing applications in the 4 types of imitations and are under review and approval.
After approval, they will be deemed to have been reviewed; the supplementary applications for consistency evaluation of Shandong New Times Pharmaceutical and Hunan Sailong Pharmaceutical are under review and approval In
.
Among them, CSPC Ouyi Pharmaceutical | CSPC Yinhu Pharmaceutical, Sinopharm Guorui Pharmaceutical, Hunan Hengsheng More than 10 companies, including pharmaceuticals, have submitted their listing applications in the 4 types of imitations and are under review and approval.
After approval, they will be deemed to have been reviewed; the supplementary applications for consistency evaluation of Shandong New Times Pharmaceutical and Hunan Sailong Pharmaceutical are under review and approval In
.
Source: CDE official website, Minet database
